Volume 65, Issue 4 pp. 465-472

Original Article

Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody

Akane Toriyama,

Akane Toriyama

Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

Department of Pathology, Juntendo University Urayasu Hospital, Chiba, Japan

Search for more papers by this author

Taisuke Mori,

Taisuke Mori

Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

Division of Pathology, National Cancer Center Research Institute, Tokyo, Japan

Search for more papers by this author

Shigeki Sekine,

Shigeki Sekine

Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

Division of Pathology, National Cancer Center Research Institute, Tokyo, Japan

Search for more papers by this author

Akihiko Yoshida,

Akihiko Yoshida

Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

Search for more papers by this author

Okio Hino,

Okio Hino

Department of Pathology and Oncology, Juntendo University, School of Medicine, Tokyo, Japan

Search for more papers by this author

Koji Tsuta,

Corresponding Author

Koji Tsuta

Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

Address for correspondence: K Tsuta, Division of Pathology and clinical Laboratories, National Cancer Center Hospital, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. e-mail: [email protected]Search for more papers by this author

Akane Toriyama,

Akane Toriyama

Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

Department of Pathology, Juntendo University Urayasu Hospital, Chiba, Japan

Search for more papers by this author

Taisuke Mori,

Taisuke Mori

Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

Division of Pathology, National Cancer Center Research Institute, Tokyo, Japan

Search for more papers by this author

Shigeki Sekine,

Shigeki Sekine

Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

Division of Pathology, National Cancer Center Research Institute, Tokyo, Japan

Search for more papers by this author

Akihiko Yoshida,

Akihiko Yoshida

Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

Search for more papers by this author

Okio Hino,

Okio Hino

Department of Pathology and Oncology, Juntendo University, School of Medicine, Tokyo, Japan

Search for more papers by this author

Koji Tsuta,

Corresponding Author

Koji Tsuta

Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

First published: 04 March 2014

https://doi.org/10.1111/his.12405

Citations: 47

Share a link

Email
Wechat
Bluesky

Abstract

Aims

The purpose of this study was to compare the immunohistochemical staining profiles of PAX8-polyclonal, PAX8-monoclonal, PAX5-monoclonal and PAX6-monoclonal antibodies in several histological types of primary thoracic and thyroid tumours. In addition, we analysed PAX8 mRNA expression by using in-situ hybridization.

Methods and results

We compared polyclonal PAX8 and monoclonal PAX8, PAX5 and PAX6 antibodies in 962 samples (687 lung carcinomas, 40 malignant pleural mesotheliomas, 138 thymic tumours and 97 thyroid tumours) using the tissue microarray technique. Among thyroid tumours, the monoclonal and polyclonal PAX8 antibodies showed a high positive rate (98.0%). Of 167 polyclonal PAX8 antibody-positive tumours, except for thyroid tumours, 54 cases tested positive for PAX5 and/or PAX6 (31 lung carcinomas and 23 thymic tumours). No PAX8 mRNA expression was detected using RNAscope (in-situ hybridization technique) other than in thyroid tumours. A portion of polyclonal PAX8 antibody-positive tumours showed cross-reactivity for PAX5 or PAX6 protein.

Conclusions

Monoclonal PAX8 antibody showed high specificity to thyroid tumours and was superior to the polyclonal antibody.

References

1Laury AR, Hornick JL, Perets R et al. PAX8 reliably distinguishes ovarian serous tumours from malignant mesothelioma. Am. J. Surg. Pathol. 2010; 34; 627–635.
PubMed Web of Science® Google Scholar
2Albadine R, Schultz L, Illei P et al. PAX8 (+)/p63 (−) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am. J. Surg. Pathol. 2010; 34; 965–969.
10.1097/PAS.0b013e3181dc5e8a
PubMed Web of Science® Google Scholar
3Haynes CM, Sangoi AR, Pai RK. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumours and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens. Cancer Cytopathol. 2011; 119; 193–201.
10.1002/cncy.20136
PubMed Web of Science® Google Scholar
4Ozcan A, Shen SS, Hamilton C et al. PAX8 expression in non-neoplastic tissues, primary tumours, and metastatic tumours: a comprehensive immunohistochemical study. Mod. Pathol. 2011; 24; 751–764.
10.1038/modpathol.2011.3
CAS PubMed Web of Science® Google Scholar
5Laury AR, Perets R, Piao H et al. A comprehensive analysis of PAX8 expression in human epithelial tumours. Am. J. Surg. Pathol. 2011; 35; 816–826.
10.1097/PAS.0b013e318216c112
PubMed Web of Science® Google Scholar
6Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F. N-terminal PAX8 polyclonal antibody shows cross-reactivity with n-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod. Pathol. 2012; 25; 231–236.
10.1038/modpathol.2011.162
CAS PubMed Web of Science® Google Scholar
7Morgan EA, Pozdnyakova O, Nascimento AF, Hirsch MS. PAX8 and PAX5 are differentially expressed in B-cell and T-cell lymphomas. Histopathology 2013; 62; 406–413.
10.1111/his.12020
PubMed Web of Science® Google Scholar
8Lorenzo PI, Jimenez Moreno CM, Delgado I et al. Immunohistochemical assessment of PAX8 expression during pancreatic islet development and in human neuroendocrine tumours. Histochem. Cell Biol. 2011; 136; 595–607.
10.1007/s00418-011-0866-3
CAS PubMed Web of Science® Google Scholar
9Tacha D, Qi W, Zhou D, Bremer R, Cheng L. PAX8 mouse monoclonal antibody [bc12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with B cells and tumours of pancreatic origin. Appl. Immunohistochem. Mol. Morphol. 2013; 21; 59–63.
CAS PubMed Web of Science® Google Scholar
10Lane D, Koprowski H. Molecular recognition and the future of monoclonal antibodies. Nature 1982; 296; 200–202.
10.1038/296200a0
CAS PubMed Web of Science® Google Scholar
11Weissferdt A, Moran CA. PAX8 expression in thymic epithelial neoplasms: an immunohistochemical analysis. Am. J. Surg. Pathol. 2011; 35; 1305–1310.
10.1097/PAS.0b013e3182260735
PubMed Web of Science® Google Scholar
12Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumours from ileal and pulmonary well-differentiated neuroendocrine tumours and pancreatic acinar cell carcinoma. Mod. Pathol. 2011; 24; 412–424.
10.1038/modpathol.2010.176
CAS PubMed Web of Science® Google Scholar
13Robson EJ, He SJ, Eccles MR. A panorama of PAX genes in cancer and development. Nat. Rev. Cancer 2006; 6; 52–62.
10.1038/nrc1778
CAS PubMed Web of Science® Google Scholar
14Morgenstern DA, Hasan F, Gibson S, Winyard P, Sebire NJ, Anderson J. PAX5 expression in nonhematopoietic tissues. Reappraisal of previous studies. Am. J. Clin. Pathol. 2010; 133; 407–415.
10.1309/AJCPZPQN0LUGKMME
CAS PubMed Web of Science® Google Scholar
15Song J, Li M, Tretiakova M, Salgia R, Cagle PT, Husain AN. Expression patterns of PAX5, c-met, and paxillin in neuroendocrine tumours of the lung. Arch. Pathol. Lab. Med. 2010; 134; 1702–1705.
PubMed Web of Science® Google Scholar
16Sica G, Vazquez MF, Altorki N et al. PAX-5 expression in pulmonary neuroendocrine neoplasms: its usefulness in surgical and fine-needle aspiration biopsy specimens. Am. J. Clin. Pathol. 2008; 129; 556–562.
10.1309/8J2PQHF603WHVL8K
PubMed Web of Science® Google Scholar
17Kanteti R, Nallasura V, Loganathan S et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-met transcription. Lab. Invest. 2009; 89; 301–314.
10.1038/labinvest.2008.168
CAS PubMed Web of Science® Google Scholar
18Abiko K, Mandai M, Hamanishi J et al. Oct4 expression in immature teratoma of the ovary: relevance to histologic grade and degree of differentiation. Am. J. Surg. Pathol. 2010; 34; 1842–1848.
10.1097/PAS.0b013e3181fcd707
PubMed Web of Science® Google Scholar

Citing Literature

Volume65, Issue4

October 2014

Pages 465-472

Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody

Abstract

Aims

Methods and results

Conclusions

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody

Abstract

Aims

Methods and results

Conclusions

References

Citing Literature

References

Related

Information